Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental hepatitis C treatment news

Show

From To
New and experimental hepatitis C treatment
Achillion Reports Interim Results on ACH-3102

Enrollment completed in pilot Phase 2a study of ACH-3102 and ribavirin for genotype 1b CC patients; up to 12 weeks of once daily ACH-3102 appears safe and well tolerated with no on-treatment virologic breakthrough observed to date.

Published
08 January 2013
From
Achillion press release
New and experimental hepatitis C treatment
Medivir announces phase III data for Simeprevir demonstrating efficacy and safety in genotype 1 hepatitis C patients

Simeprevir achieved SVR12 rates (viral cure) of 79% to 81% in the three pivotal phase III trials QUEST-1, QUEST-2 and PROMISE in genotype 1 hepatitis C patients. The overall results demonstrate that simeprevir is safe and well tolerated with a safety profile of the simeprevir treatment arms similar to the placebo control. A majority of the patients, 85-93%, were able to stop all treatment after 24 weeks.

Published
20 December 2012
From
Medivir press release
Hepatitis C treatment side-effects
Vertex hepatitis C drug Incivek gets 'black box' warning over possible fatal skin conditions

The FDA says patients taking the pill in combination with two other treatments should stop immediately if they develop a rash that grows worse or comes with symptoms like a fever, diarrhea or mouth sores.

Published
20 December 2012
From
Washington Post
Hepatitis C - First Interferon-Free Regimens Expected to Launch in 2014 in the United States and Europe

The first IFN-free regimens are expected to launch in the United States and Europe by 2014 and, once available, Decision Resources anticipates aggressive and widespread uptake of these therapies in patients who are treatment-naive as well as treatment-experienced.

Published
19 December 2012
From
HCV New Drugs Research
Pharmaceutical industry
Breaking Up With Gilead Sciences

Eventually, even perpetually bullish Wall Street analysts are going to realize the hepatitis C market is far smaller than current estimates suggest.

Published
17 December 2012
From
The Street
Pharmaceutical industry
ITPC Open letter from activists in EECA about the Galien Prix Award goint to Merck for boceprevir

November 30, representatives of ECUO and ITPCru on behalf of the Community Advisory Board in Eastern Europe and Central Asia sent an open letter of protest to the Committee of the Prix Galien expressing their concern with regard to the Galien Award going to Merck for their Hep C drug boceprevir. 

Published
06 December 2012
From
EATG
New and experimental hepatitis C treatment
Monoclonal antibody GS-6624 well tolerated by patients with hepatic fibrosis in initial safety study

Patients with hepatic fibrosis treated with monoclonal antibody GS-6624 experienced reductions to AST and ALT levels with no serious adverse events, treatment discontinuations or dose adjustments in a study presented at The Liver Meeting.

Published
04 December 2012
From
Healio Hepatology
New and experimental hepatitis C treatment
Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients

POSITRON Demonstrates Efficacy of a 12-Week All-Oral Regimen of Sofosbuvir Plus Ribavirin for Chronic Hepatitis C Patients who are Unable or Unwilling to Take Interferon

Published
27 November 2012
From
Gilead press release
New and experimental hepatitis C treatment
New second generation combination therapy for HCV - first or best in the market

This article is Part 1 in a series about Hepatitis C intended to provide an update and fundamental analysis of the companies that are actively pursuing the development of an all oral therapy for HCV.

Published
19 November 2012
From
Seeking Alpha
New and experimental hepatitis C treatment
Gilead may move ahead of rivals with hepatitis C results

Gilead Sciences Inc. (GILD) may have an edge on rivals developing new hepatitis C drugs for a potential $20 billion market after a study showed its experimental drugs cleared the liver disease virus in 100 percent of patients.

Published
15 November 2012
From
Bloomberg Businessweek
← Prev12345...22Next →

Filter by country